Cellares

“Cellares closed its Series D funding at $327 million... The IDMO model and Smart Factories promise to industrialize advanced treatments, ensuring rapid, consistent production for hundreds of thousands of patients annually by 2027.”

“The IDMO model and Smart Factories promise to industrialize advanced treatments, ensuring rapid, consistent production for hundreds of thousands of patients annually by 2027.”

“Cell therapy and precision oncology are moving from bespoke, manual processes to industrialized, automated production — a critical bottleneck breakthrough that could unlock mass patient access to next-generation treatments.”